Author: digi

Phase 3 Trials for Rare Diseases: Feasibility, Design, and Regulatory Flexibility

June 17, 2025

Phase 3 Trials for Rare Diseases: Feasibility, Design, and Regulatory Flexibility How to Design and Execute Phase 3 Trials for Rare Diseases Successfully Why Rare Diseases Pose Unique Challenges in Phase 3 Trials Conducting Phase 3 trials for rare diseases—also called orphan indications—is vastly different from trials in common conditions. Rare diseases often affect fewer…

Phase 3 (Confirmation and Monitoring)

Pharmacogenomics in Phase 4: Identifying Risk Populations and Personalizing Treatment

June 17, 2025

digi

Pharmacogenomics in Phase 4: Identifying Risk Populations and Personalizing Treatment Integrating Pharmacogenomics into Phase 4 Clinical Trials for Precision Medicine Introduction With the rise of precision medicine, understanding how genetic variations affect drug response is no longer just a research concept—it’s a clinical necessity. Pharmacogenomics, the study of how genes influence drug metabolism, efficacy, and…

Phase 4 (Post-Marketing Surveillance)

Coordinating Home Nurse Visits for Study Procedures in Decentralized Trials

June 17, 2025

digi

Coordinating Home Nurse Visits for Study Procedures in Decentralized Trials How to Coordinate Home Nurse Visits for Study Procedures in Decentralized Trials Home health visits are a cornerstone of patient-centric decentralized clinical trials (DCTs). They bring study procedures directly to participants’ homes, improving retention and reducing the need for travel. However, coordinating these visits—especially across…

Decentralized Clinical Trials (DCTs), Home Health Visits

Using Niche CROs for Device and Diagnostic Studies

June 17, 2025

digi

Using Niche CROs for Device and Diagnostic Studies Leveraging Niche CROs for Medical Device and Diagnostic Clinical Trials Medical device and diagnostic studies involve unique regulatory and operational requirements that differ significantly from traditional pharmaceutical trials. From analytical performance to usability testing, device developers must adhere to FDA’s QSR (21 CFR Part 820), EU MDR,…

Contract Research Organizations (CROs), Niche/Specialty CROs

Optimizing SDV Frequency for Different Trial Types: Strategies for Efficient Monitoring

June 17, 2025

digi

How to Optimize SDV Frequency for Different Clinical Trial Types Source Data Verification (SDV) is a foundational aspect of clinical trial monitoring, ensuring that the data captured in the CRF matches the original source documentation. However, the frequency and extent of SDV need not be uniform across all trials. Over-verification can waste resources, while under-verification…

Site Management and Monitoring, Source Data Verification

Integrating Real-World Data (RWD) into Early Clinical Development

June 17, 2025

digi

Integrating Real-World Data (RWD) into Early Clinical Development Leveraging Real-World Data to Shape Early Clinical Research Strategies Introduction Traditionally, real-world data (RWD) has been associated with post-marketing studies or Phase 4 evidence generation. But in recent years, sponsors have started to leverage RWD much earlier—during Phase 1 or even preclinical stages. By integrating electronic health…

Phase 1 (Safety and Dosage)

Leveraging Electronic Health Records for Recruitment in Clinical Trials

June 17, 2025

digi

How to Leverage Electronic Health Records for Clinical Trial Recruitment Recruiting the right patients for a clinical trial remains one of the biggest operational challenges. Traditional methods often rely on physician referrals or advertisements, which can be slow and yield limited eligible candidates. Electronic Health Records (EHRs) offer a powerful solution by enabling pre-screening and…

Clinical Research Operations, Patient Enrollment Strategies

Case Studies in Educational and Vaccination Trials – Clinical Trial Design and Protocol Development

June 17, 2025

digi

Case Studies in Educational and Vaccination Trials – Clinical Trial Design and Protocol Development “Examining Case Studies in Education and Vaccination Trials” Introduction to Case Studies in Educational and Vaccination Trials In the world of clinical trials, education and vaccination studies hold a significant place. They are essential in understanding the effectiveness and potential side…

Clinical Trial Design and Protocol Development, Cluster Randomized Trials

Role of Portals in Two-Way Patient Communication During Clinical Trials

June 17, 2025

digi

Role of Portals in Two-Way Patient Communication During Clinical Trials How Patient Portals Enable Two-Way Communication in Clinical Trials Effective communication is foundational to successful clinical trials. Traditionally, interaction between patients and study teams has been limited to scheduled visits or phone calls. However, this static approach often leads to misunderstandings, missed updates, and disengaged…

Patient Engagement Tools, Patient Recruitment and Retention

What to Expect During Routine Monitoring Visits in Clinical Trials

June 17, 2025

digi

What to Expect During Routine Monitoring Visits in Clinical Trials Routine Monitoring Visits (RMVs) are a critical component of ongoing oversight in clinical trials. Conducted by Clinical Research Associates (CRAs), these visits ensure that the investigative site complies with the protocol, Good Clinical Practice (GCP), and sponsor expectations. For investigators and study coordinators, knowing what…

Routine Monitoring Visits, Site Management and Monitoring